Leap Therapeutics Inc (LPTX) FinancialsLPTXLeap Therapeutics Inc

Evaluating the bottom line, Leap Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -196.76%, provide a clear picture of how effectively LPTX converts its operational activities into shareholder value.

In the context of the broader market, LPTX competes directly with industry leaders such as RLYB and PLUR. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, LPTX's gross margin of N/A stands against RLYB's 100.00% and PLUR's 33.53%. Such benchmarking helps identify whether Leap Therapeutics Inc is trading at a premium or discount relative to its financial performance.